文献速递慢阻肺间质性肺疾病

米氮平缓解慢阻肺或间质性肺疾病患者严重呼吸困难:BETTER-B 国际多中心随机对照试验

Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial.
PubMed 文献 · Lancet Respir Med · 2024-09-09

这项国际多中心3期双盲随机安慰剂对照试验纳入225例慢阻肺或间质性肺疾病伴3-4级呼吸困难患者,评估米氮平15-45 mg/日共56天的疗效。研究不建议米氮平用于缓解严重呼吸困难。

要点

  • 米氮平15-45 mg/日治疗56天未改善慢阻肺或间质性肺疾病患者的严重呼吸困难。
  • 米氮平组不良反应发生率为64%(72/113),高于安慰剂组的40%(44/110)。
  • 基于该结果,不推荐米氮平用于缓解严重呼吸困难。

核心结论

  • 米氮平15-45 mg/日共56天不能改善慢阻肺或间质性肺疾病患者的严重呼吸困难,且可能引起不良反应,不推荐用于此目的。

研究设计与样本

  • 国际多中心3期平行组双盲随机安慰剂对照试验,在7个国家16个中心开展。
  • 纳入225例慢阻肺和/或间质性肺疾病且改良MRC呼吸困难量表3级或4级的成人,按1:1随机分配至米氮平组(113例)或安慰剂组(112例)。
  • 米氮平初始剂量15 mg,最大增至45 mg/日,治疗56天,结束时逐渐减量,随访至180天。
  • 主要结局为治疗开始后第56天过去24小时最严重呼吸困难0-10数字评分量表(NRS)评分,在改良意向治疗人群中用多变量多水平重复测量模型分析。

主要发现

  • 米氮平组72/113例(64%)发生215次不良反应,安慰剂组44/110例(40%)发生116次不良反应。
  • 米氮平组6例(5%)发生11次严重不良事件,安慰剂组7例(6%)发生8次严重不良事件;米氮平组1例(1%)发生可疑非预期严重不良反应。
  • 第56天米氮平组死亡3例、安慰剂组死亡2例;第180天米氮平组死亡7例、安慰剂组死亡11例。

临床怎么用

  • 对于慢阻肺或间质性肺疾病患者的严重呼吸困难,不应使用米氮平15-45 mg/日作为缓解治疗。

局限性

  • 研究把握度不足,主要终点效应未达到预设治疗效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breathlessness frequently becomes severe among people with respiratory disease. Mirtazapine, a widely used antidepressant, has shown promise in the modulation of respiratory sensation and the response to it, as well as reducing feelings of panic, which often accompanies breathlessness. We aimed to determine the effectiveness of mirtazapine to alleviate severe persisting breathlessness. METHODS: This international, multicentre, phase 3, parallel-group, double-blind, randomised, placebo-controlled trial across 16 centres in seven countries (Australia, Germany, Ireland, Italy, New Zealand, Poland, and the UK), recruited adults with chronic obstructive pulmonary disease (COPD), interstitial lung diseases, or both, and grade 3 or 4 of the modified Medical Research Council breathlessness scale. Consenting participants were randomly assigned (1:1) to receive oral mirtazapine or matching placebo for 56 days. Randomisation was by minimisation. The initial mirtazapine dose was 15 mg, escalating to a maximum of 45 mg per day, tapered at treatment end. Participants, caregivers, assessors, and investigators were masked to group assignment. The primary outcome was worst breathlessness in the preceding 24 h measured on a 0-10 numerical rating scale (NRS), at 56 days post-treatment start, with follow-up to 180 days. The primary analysis was performed in the modified intention-to-treat population using multivariable multi-level repeated measures model. This trial was registered with ISRCTN (ISRCTN10487976 and ISRCTN15751764 [Australia and New Zealand]) and EudraCT (2019-002001-21) and is complete. FINDINGS: Between Feb 4, 2021 and March 28, 2023, we enrolled 225 eligible participants (148 men and 77 women, 113 to the mirtazapine group and 112 to the placebo group). The median age was 74 years (IQR 67-78). No evidence of a difference was found in worst breathlessness at day 56 between mirtazapine and placebo (difference in adjusted mean NRS score was 0·105 [95% CI -0·407 to 0·618]; p=0·69). Although the study was underpowered, the primary endpoint effect did not reach the pre-specified treatment effect of 0·55 for worst breathlessness score reduction that the study was powered to detect for the primary analysis. There were 215 adverse reactions in 72 (64%) of 113 participants in the mirtazapine group versus 116 in 44 (40%) of 110 participants in the placebo group; 11 serious adverse events in six (5%) participants in the mirtazapine group versus eight in seven (6%) participants in the placebo group; and one (1%) suspected unexpected serious adverse reaction in the mirtazapine group. At day 56, there were three deaths in the mirtazapine group and two deaths in the placebo group. At day 180, there were seven deaths in the mirtazapine group and 11 deaths in the placebo group. INTERPRETATION: Our findings suggested that mirtazapine of doses 15 to 45 mg daily over 56 days does not improve severe breathlessness among patients with COPD or interstitial lung diseases and might cause adverse reactions. Based on these findings, we do not recommend mirtazapine as a treatment to alleviate severe breathlessness. FUNDING: EU Horizon 2020 (grant agreement No. 825319); Cicely Saunders International Breathlessness Programme; National Institute for Health and Care Research Applied Research Collaboration South London; Australian National Health and Medical Research Council-EU (application ID: APP1170731).

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Higginson IJ, Brown ST, Oluyase AO, et al. Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial. Lancet Respir Med. 2024. PMID: 39265600. doi:10.1016/S2213-2600(24)00187-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。